NASDAQ · SEER
Healthcare · Biotechnology
$1.59
Up+$0.00 (+0.00%)
Updated Nov 13, 2026, 12:35 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SEER
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 12, 2026
SEER closed at $1.59 after 21 trading sessions, down 22.06% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | $1.60 | $1.65 | $1.56 | $1.59 | 62.81K |
| Nov 11, 2026 | $1.64 | $1.67 | $1.56 | $1.59 | 260.82K |
| Nov 10, 2026 | $1.67 | $1.705 | $1.57 | $1.61 | 131.18K |
| Nov 9, 2026 | $1.65 | $1.74 | $1.65 | $1.68 | 99.36K |
| Nov 6, 2026 | $1.63 | $1.70 | $1.62 | $1.63 | 198.46K |
| Nov 5, 2026 | $1.70 | $1.78 | $1.62 | $1.63 | 108.24K |
| Nov 4, 2026 | $1.77 | $1.78 | $1.70 | $1.70 | 62.84K |
| Nov 3, 2026 | $1.75 | $1.78 | $1.70 | $1.73 | 139.58K |
| Nov 2, 2026 | $1.68 | $1.78 | $1.6501 | $1.73 | 422.7K |
| Oct 30, 2026 | $1.89 | $1.895 | $1.615 | $1.68 | 516.54K |
| Oct 29, 2026 | $2.00 | $2.08 | $1.92 | $1.94 | 177.56K |
| Oct 28, 2026 | $1.98 | $2.02 | $1.945 | $1.99 | 70.85K |
| Oct 27, 2026 | $1.90 | $2.01 | $1.89 | $1.96 | 122.28K |
| Oct 26, 2026 | $1.99 | $1.99 | $1.93 | $1.93 | 59.31K |
| Oct 23, 2026 | $1.95 | $2.00 | $1.91 | $1.97 | 147.08K |
| Oct 22, 2026 | $2.03 | $2.035 | $1.955 | $1.97 | 106.02K |
| Oct 21, 2026 | $1.97 | $2.0999 | $1.97 | $2.03 | 121.99K |
| Oct 20, 2026 | $2.03 | $2.05 | $1.98 | $1.98 | 553.74K |
| Oct 19, 2026 | $2.04 | $2.09 | $2.015 | $2.02 | 43K |
| Oct 16, 2026 | $2.03 | $2.10 | $2.01 | $2.03 | 147.37K |
| Oct 15, 2026 | $2.08 | $2.095 | $2.04 | $2.04 | 173.29K |
The latest Smart Investors Daily articles mentioning SEER.
Company
Market Activity
Research & News
SEER research
Company profile and research snapshot.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 4, 2026 | Canaccord Genuity | Buy | — |
| Aug 13, 2024 | Morgan Stanley | Equal-Weight | — |
| Mar 5, 2024 | Morgan Stanley | Equal-Weight | — |
| Feb 21, 2023 | Morgan Stanley | Equal-Weight | — |
| Jan 4, 2023 | B of A Securities | Underperform | — |
No generated briefing is available yet.
Yahoo · Nov 11, 2026
Seer Inc (SEER) posted sequential revenue growth and a narrower net loss while lowering its 2026 outlook to $13.5-$14.5 million amid academic funding constraints and activist-campaign uncertainty.
Yahoo · Nov 11, 2026
Funding strain and slower purchasing are pushing Seer's late-stage deals later.
Yahoo · Nov 10, 2026
Seer (NASDAQ:SEER) lowered its 2026 revenue outlook after research funding constraints and uncertainty surrounding its future delayed customer purchases, even as third-quarter revenue rose from the preceding quarter. The proteomics technology company now expects full-year revenue of $13.5 million t
Yahoo · Nov 10, 2026
REDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended September 30, 2026. Seer reported third-quarter revenue of $4.0 million, compared with $3.1 million in the second quarter of 2026, and ended the quarter with approximately $198.1 million in cash, cash equivalents and investments. Seer also updated its full-year 20
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SEER.
